Monograph

N07AA01 - Neostigmine

Propably not porphyrinogenic

Rationale

No data pointing to CYP-interaction. References consider it safe.

Chemical description

Cholinesterase inhibitor of short duration used in intestinal and bladder atonia. Hydrolyzed by cholinesterases. No data pointing to CYP-metabolism. Australian list: safe EPI-list: use South African list: use

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes N07A / N07AA or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Neostigminemethylsulfaat · Neostigminemethylsulfaat CF 0,5 mg/ml, injectievloeistof · Prostigmin · Prostigmin 0,5 mg/ml, oplossing voor injectie

Belgium

Prostigmine · Prostigmine 0.5 mg/ml solv. pour prép. parent. s.c./i.v./i.m. amp. · Prostigmine 2.5 mg/ml solv. pour prép. parent. s.c./i.v./i.m. amp.

United Kingdom

Neostigmine · Neostigmine 10mg/5ml oral solution · Neostigmine 15mg tablets · Neostigmine 15mg/5ml oral solution · Neostigmine 2.5mg/1ml solution for injection ampoules · Neostigmine 2.5mg/5ml oral solution · Neostigmine 25mg/5ml oral solution · Neostigmine 30mg/5ml oral solution · Neostigmine 5mg/5ml oral solution · Prostigmin · Prostigmin 15mg tablets

Denmark